Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Mar 2015
Price :
$35
*
At a glance
- Drugs Pardoprunox (Primary) ; Levodopa
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms MONDRIAN
- Sponsors Solvay Pharmaceuticals
- 14 Jun 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
- 20 Apr 2010 Additional trial location (Albania) added as reported by ClinicalTrials.gov (NCT00407095) record.
- 20 Apr 2010 Additional trial location (Albania) added as reported by ClinicalTrials.gov (NCT00407095) record.